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Abstract
Background: Although highly active antiretroviral therapy (HAART) has dramatically reduced the morbidity and mortality
associated with HIV infection, a number of antiretroviral toxicities have been described, including myocardial toxicity
resulting from the use of nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs). Current treatment guidelines
recommend the use of HAART regimens containing two NRTIs for initial therapy of HIV-1 positive individuals; however,
potential cardiotoxicity resulting from treatment with multiple NRTIs has not been addressed.
Methodology/Principal Findings: We examined myocardial tissue from twelve CD8 lymphocyte-depleted adult rhesus
macaques, including eight animals infected with simian immunodeficiency virus, four of which received combined
antiretroviral therapy (CART) consisting of two NRTIs [(9-R-2-Phosphonomethoxypropyl Adenine) (PMPA) and (+/2)-beta-
29,39-dideoxy-5-fluoro-39-thiacytidine (RCV)] for 28 days. Multifocal infiltrates of mononuclear inflammatory cells were
present in the myocardium of all macaques that received CART, but not untreated SIV-positive animals or SIV-negative
controls. Macrophages were the predominant inflammatory cells within lesions, as shown by immunoreactivity for the
macrophage markers Iba1 and CD68. Heart specimens from monkeys that received CART had significantly lower virus
burdens than untreated animals (p,0.05), but significantly greater quantities of TNF-a mRNA than either SIV-positive
untreated animals or uninfected controls (p,0.05). Interferon-c (IFN-c), IL-1b and CXCL11 mRNA were upregulated in heart
tissue from SIV-positive monkeys, independent of antiretroviral treatment, but CXCL9 mRNA was only upregulated in heart
tissue from macaques that received CART.
Conclusions/Significance: These results suggest that short-term treatment with multiple NRTIs may be associated with
myocarditis, and demonstrate that the CD8-depleted SIV-positive rhesus monkey is a useful model for studying the
cardiotoxic effects of combined antiretroviral therapy in the setting of immunodeficiency virus infection.
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Introduction
Human immunodeficiency virus (HIV) infection has been
associated with a variety of diseases of the cardiovascular system,
including myocarditis [1,2,3], atherosclerosis and coronary heart
disease [4,5,6,7,8,9,10,11], and cardiomyopathy and ventricular
dysfunction [12]. Myocarditis is the most common manifestation
and is thought to result in dilated cardiomyopathy (2,4). Although
HIV RNA, [13] DNA [14] and HIV-1 gp120 [15] have been
localized infrequently in cardiomyocytes of HIV positive patients
with myocarditis, the direct involvement of HIV infection and
replication in the dysfunction of cardiomyocytes and in the
pathogenesis of HIV-associated cardiac disease remains contro-
versial. An indirect but more conspicuous role in the pathogenesis
of HIV myocarditis and cardiomyopathy has been attributed to
infected and/or immune activated inflammatory cells infiltrating
the myocardium. Interestingly, myocarditis and dilated cardio-
myopathy have also been reported in pathogenic simian
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14429immunodeficiency virus (SIV) infection of rhesus macaque
monkeys [16,17].
The prevalence of myocarditis since the advent of HAART has
not been well defined; however, Pugliese and colleagues reported
myocardial disease in 52% of 544 patients treated late in the
course of AIDS with NRTIs versus 19% of 498 patients treated
with HAART [18]. Although HAART has been credited with
reducing virus burdens in plasma and lymphoid tissues, improving
peripheral CD4
+ T lymphocyte numbers and immune function
and prolonging AIDS-free survival in HIV infected individuals
[19,20], cardiovascular disease and other complications that arise
due to antiretroviral toxicity and immune reactivation continue to
be problematic [21,22,23,24]. Antiretroviral therapy has been
associated with an increased risk of cardiovascular disease in HIV
positive patients [7,25,26], although this remains controversial
[8,10,27]. Myocardial toxicity resulting from treatment with
NRTIs and non-nucleoside reverse transcriptase inhibitors
(NNRTIs) has been reported previously; suspected mechanisms
include mitochondrial toxicity and the formation of reactive
oxygen species (ROS) within cardiac myocytes [28,29]
[29,30,31,32,33]. Furthermore, chronic exposure to NRTIs,
NNRTIs, or protease inhibitors (PIs) can cause oxidative stress
to endothelial cells, resulting in enhanced cytokine production and
recruitment of mononuclear cells [34].
During routine histopathological examination, myocarditis was
observed in four of four CD8
+ lymphocyte-depleted rhesus
macaques that had been infected with SIVmac251 and treated
with the NRTIs PMPA and RCV for 28 days. In contrast,
myocarditis was not evident in CD8-depleted, SIV-infected
macaques that did not receive CART, suggesting possible
antiretroviral agent-mediated myocardial toxicity. The present
study was conducted to investigate the pathogenesis of myocarditis
in these animals.
Methods
Ethic Statement
All animal studies were performed in accordance with federal
laws and regulations, international accreditation standards, and
institutional policies, including approval by the New England
Primate Research Center (NEPRC), Harvard Medical School
Animal Care and Use Committee of Harvard University (IACUC
protocol # 03076). All animals received environmental enrich-
ment and were monitored daily for evidence of disease and
changes in attitude, appetite, or behavior suggestive of illness.
Appropriate clinical support was administered under the direction
of the attending veterinarian and included analgesics, antibiotics,
intravenous fluids, and other supportive care. Steps were taken to
minimize suffering and discomfort. Animals were pair or group-
housed when possible. Surgical and sampling procedures were
kept to a minimum and were conducted under anesthesia followed
by appropriate analgesics for pain and discomfort, which was
carefully monitored. Animals were euthanized under anesthesia
when they presented with advanced stages of AIDS; criteria for
euthanasia included 15% weight loss in two weeks, unresponsive
opportunistic infection, persistent anorexia, intractable diarrhea,
progressive neurologic signs, significant cardiac or pulmonary
signs or other serious illness.
Tissues
This retrospective study used archived frozen left ventricles that
had been collected during the necropsy of CD8 lymphocyte-
depleted rhesus macaques (control group; n=4), CD8 lympho-
cyte-depleted and SIVmac251-infected rhesus macaques with
simian AIDS (untreated group; n=4), and CD8 lymphocyte-
depleted and SIVmac251-infected rhesus macaques with AIDS
that had been treated with a combined antiretroviral regimen
(CART group; n=4) (Table 1). The CART regimen consisted of
28 days of therapy with PMPA (9-R-2-Phosphonomethoxypropyl
Adenine), at 30 mg/kg/day and Racivir (RCV, (+/2)-beta-29,39-
dideoxy-5-fluoro-39-thiacytidine), at 10 mg/kg/day, initiated 28
days after infection with SIV, and administered as once-daily
subcutaneous injections, as described elsewhere [35]. Portions of
left ventricle collected at necropsy were immediately immersed in
RNAlater solution (Qiagen Inc., Valentia, CA), held at 4uC
overnight, and frozen the following day at –80uC, according to the
manufacturer’s recommendations. Histopathologic examination
was performed on hematoxylin and eosin (H&E) stained sections
of cardiac tissue that were fixed in 10% neutral buffered formalin
before routine processing and embedding in paraffin.
Table 1. Animals and Therapy.
Group Case number Age (days) DAD (days) CART (days) AIDS Plasma virus load (log10 copies/ml) Myocarditis
21 dpi terminal
Control Case 1 1668 - No - -
Case 2 1549 - No - -
Case 3 1794 - No - -
Case 4 1726 - No - -
Untreated Case 5 3116 70 No Yes 7.7 6.7 -
Case 6 3487 57 No Yes 7.7 7.6 -
Case 7 3489 63 No Yes 7.1 7.7 -
Case 8 4606 85 No Yes 6.6 7.6 -
CART Case 9 4025 57 28 No 7.4 5.4 ++
Case 10 7584 57 28 No 7.1 6.1 +++
Case 11 3782 57 28 No 6.5 4.6 ++
Case 12 3778 57 28 No 7.2 5.8 ++
DAD: duration of infection in days.
doi:10.1371/journal.pone.0014429.t001
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Immunohistochemistry (IHC) was used to characterize the
phenotype of immune cells in myocardial lesions and to localize
chemokines, proinflammatory cytokines, and adhesion molecules
in sections of myocardium. The antibodies used were directed
against macrophages (Iba-1, Waco, Richmond, VA), activated
macrophages (CD68, clone KP-1, Dako Cytomation, Carpinteria,
CA), T lymphocytes (CD3, Dako), CD4
+ cells (CD4, clone 1F6,
Vector Laboratories, Burlingame, CA), CD8
+ cells (CD8, clone
1A5, Vector Labs), B lymphocytes (CD20, clone L26, Dako), the
inactive precursor of IL-18 (pro-IL-18, R&D Systems, Minneap-
olis, MN), the chemokine CXCL9 (also known as monokine
induced by gamma interferon, or MIG, R&D Systems), the
adhesion molecule ICAM-1 (CD54, clone 54CO4, LabVision,
Fremont, CA) and cytomegalovirus (CMV) (rabbit anti-CMV
serum, a gift from Peter A. Barry, California National Primate
Research Center, University of California at Davis). IHC was
performed on 5 mM sections of formalin-fixed, paraffin-embedded
(FFPE) tissues, using an ABC immunoperoxidase technique as
described elsewhere [36]. Briefly, FFPE tissue sections were
deparaffinized in xylene and rehydrated through graded ethanol to
distilled water. Microwave antigen retrieval was performed using
citrate buffer (Dako Corp., Carpinteria, CA) for all antibodies
except CD8, for which antigen retrieval was accomplished using a
pressure cooker and Trilogy solution (Cell Marque, Rocklin, CA).
Endogenous peroxidase activity was blocked in 3% hydrogen
peroxide in phosphate buffered saline (PBS), and non-specific
protein binding was blocked with Protein Block (Dako). After
incubating with the primary antibody, tissue sections were reacted
sequentially with biotinylated secondary antibody (Dako), horse-
radish peroxidase-conjugated streptavidin (Dako), and the chro-
mogenic substrate 3, 39-diaminobenzidene (DAB, Dako), and
counterstained with hematoxylin (Sigma Chemical Co., St. Louis,
MO). The source and dilution of antibodies used in this study are
summarized in Table 2.
Double immunolabeling and spectral imaging
Double label immunohistochemistry was performed on depar-
affinized and rehydrated formalin-fixed paraffin embedded tissue
sections by sequentially incubating with the first primary antibody
and its corresponding secondary antibody followed by detection of
antigen-antibody complex using the Fast Red Substrate-Chromo-
gen System (Dako Cytomation) catalyzed by ABC-Alkaline
Phosphatase (Vectastain ABC-AP Standard Kit, Vector). The
tissue sections were subsequently incubated with the second
primary antibody and respective secondary antibody. The second
immune complex was visualized by DAB chromogen (DakoCy-
tomation) as in single immunohistochemistry and the tissue
sections were counterstained with hematoxylin. Images of labeled
sections were acquired using an Olympus Vanox-S AHBS
microscope interfaced with a liquid crystal tunable filter based
camera (CRI, Woburn MA, USA) from 420 nm to 720 nm at 20
nm steps. The spectral components were unmixed using single
stain controls as described elsewhere [17,37]. Spectrally unmixed
individual images were then pseudo-colored and combined.
Masson’s trichrome stain
The extent of myocardial fibrosis was assessed by labeling
collagen fibers in myocardial sections by the Masson’s trichrome
technique (Trichrome Stain, Newcomer supply, Middleton, WI).
Briefly, FFPE tissue sections were deparaffinized in xylene,
rehydrated in graded ethanol and post-fixed in Bouin’s fixative
for one hour at 55uC. The nuclei and collagen were sequentially
stained with equal volumes of ferric chloride solution and alcoholic
hematoxylin and trichrome solution, respectively.
In situ hybridization (ISH)
Productively infected cells were identified in FFPE myocardial
tissue sections by ISH for SIV RNA, as described elsewhere [36].
Tissue sections were deparaffinized in xylene and rehydrated in
graded ethanol to diethyl pyrocarbonate (Sigma) treated water.
Endogenous alkaline phosphatase activity was blocked with
levamisole (Sigma), and sections were hydrolyzed in HCl (Sigma),
digested with proteinase K (Roche Diagnostics Corp., Indianap-
olis, IN), acetylated in acetic anhydride (Sigma), and hybridized
overnight at 50uC with a digoxigenin-labeled antisense riboprobe
which spans the entire genome of the SIVmac239 molecular clone
of SIVmac251 (Lofstrand Labs, Gaithersburg, MD). The following
day, tissue sections were washed extensively and bound probe was
detected by IHC, using alkaline phosphatase-conjugated sheep
anti-digoxigenin F(ab) fragments (Roche) and the chromogen
nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate
(NBT/BCIP, Roche). Sections were counterstained with nuclear
fast red (Vector Labs). Sections of brain from a rhesus macaque
with SIVmac251 encephalitis served as both positive control (when
incubated with SIV antisense probe) and negative control (when
reacted with SIV sense probe). Additional negative controls
included sections of myocardial tissue from uninfected macaques
reacted with SIV antisense probe.
Total RNA isolation and quantification
Total RNA was isolated from frozen left ventricle specimens.
Briefly, 75-100 mg of tissue was homogenized in 1.5 ml of Trizol
reagent (Invitrogen Corp., Carlsbad, CA) using a bead beater and
1 mm diameter silica beads (Biospec Products Inc., Bartlesville,
OK). After homogenization, the homogenate was removed to a
new tube, 0.2 volumes of chloroform was added, and the aqueous
phase was collected after centrifugation at 8,0006g for 5 minutes
at 4uC. The aqueous phase was combined with an equal volume of
70% ethanol, one ml of 4M guanidinium isothiocyanate was
added, and the mixture was loaded onto a RNeasy spin column
(Qiagen). After on-column DNase treatment (Qiagen), the total
RNA was eluted in RNase free water, 2 units/ml of recombinant
RNase inhibitor (RNasin, Promega) was added, and the RNA was
frozen at –80uC. The amount of RNA extracted from tissue
Table 2. Antibodies used for immunohistochemistry.
Antigen Source Antibody type* Dilution
CD3 Dako Polyclonal 1:600
CD4 Vector IgG1 1:40
CD8 Vector IgG1 1:50
CD20 Dako IgG2a 1:175
CD68 Dako IgG1 1:410
Iba-1 Waco Polyclonal 1:1,000
ICAM-1 Labvision IgG1 1:100
CXCL9/MIG R&D Systems IgG 1:100
IL-18-pro R&D Systems IgG 1:100
CMV Non commercial Polyclonal 1:1600
*CXCL9/MIG and IL-18-pro antibodies were raised in goat; CD3 and Iba 1
polyclonal antibodies were raised in rabbit.
doi:10.1371/journal.pone.0014429.t002
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assay (Invitrogen), adhering to the manufacturer’s instructions,
and measuring fluorescence for 0.1 seconds at excitations and
emissions of 485 nm and 535 nm, respectively, using a Victor
3 V
1420 Multilabel Counter (Perkin Elmer, Waltham, MA).
TaqMan real time RT-PCR
The absolute quantification of SIV Gag, TNF-a and RPL13A
transcripts in total RNA from left ventricle and spleen specimens
was conducted using TaqMan probes and TaqMan One-Step
RT-PCR master mix reagents (Applied Biosystems, Foster City,
CA) on an ABI Prism 7700 thermal cycler (Applied Biosystems).
Total RNA from myocardial tissues (100 ng per specimen) was
combined with 200 nM each of forward and reverse primers, 1x
One-Step RT-PCR master mix and, 100 nM of TaqMan probe in
a5 0ml reaction. For use as internal RNA standards, known copy
numbers of RNA transcripts were serially diluted in RNase free
water from 10
6 through 10
1 copies. Amplification data were
analyzed using Sequence Detection Version 1 software (Applied
Biosystems).
SYBR Green real time PCR
To investigate the expression of cytokines and chemokines in
myocardial tissue, 20 ng of cDNA from each specimen was used as
template in a 25 ml reaction containing 1x SYBR Green master
mix (Applied Biosystems) and forward and reverse primers (100
mM each). Reactions were conducted in duplicate on an ABI 7500
thermal cycler, with the following conditions: 1 cycle of 96uC for 2
minutes; 45 cycles of 96uC for 30 seconds and 60uC for 1 minute
followed by one cycle of dissociation from 96uCt o6 0 uC. At the
end of each run, the data were analyzed using Sequence Detection
Version 1 software (Applied Biosystems). Fold-regulation of
expression of each gene was calculated from the Ct values after
normalizing with the Ct values obtained for RPL13A mRNA, the
internal control gene. The primers used in the study are shown in
Table 3.
Statistical analysis
A two-tailed, nonparametric Mann-Whitney U test was used to
compare the copy numbers of SIV and TNF-a mRNA transcripts,
which are reported as median values 6 semi-interquartile range.
Significant differences were assumed for probability values of
p,0.05.
Results
Histopathology
Histopathological examination of routine H&E sections re-
vealed multifocal infiltrates of mononuclear inflammatory cells
(morphologically consistent with macrophages and lymphocytes),
which were dissecting and compressing cardiomyocytes in sections
of myocardium from all four animals in the CART group.
Necrosis and degeneration of cardiomyocytes was apparent within
the lesions, with no evidence of fibrosis (Figure 1). In addition,
reactive, hypertrophic endothelial cells were observed bulging into
vascular lumens throughout the myocardial sections of 3 of the 4
Table 3. Primers and probes.
Accession Number Gene Primer
Primers and probes used for TaqMan assay
M33262 SIV gag Forward: AGAAAGCCTGTTGGAGAACAAAGAAGG
Reverse: AGTGTGTTTCACTTTCTCTTCTGCGTG
Probe: 6FAM CTGTCTGCCTCATCTGGTGC TAMRA
NM_001047149 TNF-a Forward: CTCTTCAAGGGCCAAGGCT
Reverse: GATGCGGCTGATGGTGTG
Probe: 6FAMCCCCTCCAACCATGTGCTCCTCA TAMRA
FM208094 RPL13A Forward: CGAGAAAGTTTGCCTATCTGGG*
Reverse: GGTGGTTGTCACTGCCTGGTA*
Probe: 6FAM CCTGGCTCACGAGGTTGGCTGG TAMRA
Primers used for SYBR Green assay
U19845 IL-1b Forward: TGGCATCCAGCTACAAATCTCCCA
Reverse: AAGGGAATCAAGGTGCTCAGGTCA
NM_001042733 IL-6 Forward: AGCCACTGACCTCTTCAGAACGAA
Reverse: GTGCCTCTTTGCTGCTTTCACACA
NM_001044727 IL-10 Forward: TCCTTGCTGGAGGACTTTAAGGGT
Reverse: TCACATGCTCCTTGATGTCTGGGT
NM_001032834 IL-18 Forward: TTCATTGACCAAGGAAATCGGCCC
Reverse: GCCATACCTCTAGGCTGGCTATCTTT
NM_001032905 IFN-c Forward: GACTCGAATGTCCAACGCAAAGCA
Reverse: TCGACCTCGAAACATCTGACTCCT
NM_001032936 CXCL9 Forward: TGGGCATCATCTTCCTGGTTCTGA
Reverse: TTTCTCGCAGGAAAGGTTTGGAGC
NM_001032950 CXCL11 Forward: TGTCTTTGCATAGGCCCTGGAGTA
Reverse: GCTTGCTTCGATTTGGGATTTAGGC
NM_001047135 ICAM-1 Forward: TCCGTCAAAGTGAATTGCAGTGCC
Reverse: CCCATCAGGGCAGTTTGAATAGCA
Note:
* RPL13A primer set was used for both TaqMan and SYBR Green assays.
doi:10.1371/journal.pone.0014429.t003
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or significant inflammatory foci were present in the myocardial
sections from any animals in either the control group or the
untreated SIV positive animals with simian AIDS. The absence of
intralesional fibrosis in the myocardium of affected animals was
confirmed by Masson’s trichrome stain, which revealed that there
was no significant difference in the amount of collagen present
within the myocardium of animals among all three groups
(Figures 2A and 2B). The pericardium was normal in all
animals.
Myocardial lesions are composed of macrophages and
lymphocytes
IHC was used to characterize the inflammatory infiltrates in the
myocardium. Inflammatory foci were composed largely of Iba-1
expressing cells, compatible with macrophage lineage; moreover,
60–80% of the Iba-1 positive cells also expressed the CD68
glycoprotein, suggestive of an activated phenotype (Figure 3).
IHC failed to reveal significant expression of CD8 (which is
expressed by both CD8
+ T lymphocytes and natural killer (NK)
cells) or CD20 (which identifies B lymphocytes) within inflamma-
tory foci (Figures 4A and 4B). Because small numbers of CD3
+
cells had been localized within the inflammatory foci by single-
label IHC in the absence of significant CD8 expression,
multiparameter IHC and spectral imaging were used to defini-
tively identify the phenotype of intralesional T lymphocytes. Dual-
label IHC for CD3 and CD4 expression revealed small numbers of
CD3
+/CD4
+ double-positive lymphocytes and less frequent
CD3
+/CD4
- cells, which were assumed to be CD3
+/CD8
+ T
lymphocytes (Figure 5). Taken together, these results indicate
that the inflammatory foci were primarily composed of activated
macrophages and small numbers of CD4
+ positive helper T
lymphocytes. Despite the abundance of activated macrophages in
the myocardial lesions, expression of pro-IL-18, the inactive
precursor of the proinflammatory cytokine IL-18, was confined to
faint cytoplasmic reactivity in a minority of the macrophages
present in the inflammatory foci (Figures 4C and 4D).
Virus burden is significantly lower in the myocardium of
animals that received CART
ISH for SIVmac239 RNA revealed veryfew productively infected
cells in the myocardium of either untreated animals or those that
Figure 1. Myocardial lesions are present in all four monkeys that receive CART. H & E stained sections of left ventricle from CD8
+ cell-
depleted, uninfected control macaque (A) and SIV-positive untreated macaque (B), showing normal cardiomyocytes with cross striations. In contrast,
sections of myocardium from monkeys that received CART contained multifocal infiltrates of mononuclear inflammatory cells that separated
cardiomyocytes (C), cardiomyocytolysis and necrosis (arrow heads in D and E) and hypereosinophilia with loss of cross striations in cardiomyocytes
(arrow in F). Hematoxylin & eosin stain. (400X).
doi:10.1371/journal.pone.0014429.g001
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viral RNA by TaqMan real time RT-PCR revealed a significantly
lower virus burden in the myocardium of animals that received
CART as compared to the myocardium of untreated animals
(median values of 4.1060.18 versus 4.8560.09 log10 SIV copies/
mg, respectively; p,0.05) (Figure 6A). These results indicate that
the myocardium is not a primary target organ for virus replication in
CD8 lymphocyte-depleted animals, and suggest that the lesions
present in the myocardium of animals in the CART group are not
directly associated with SIV infection. In addition to lower
myocardial tissue virus burden, CART was associated with a
significantly lower terminal plasma virus load (Table 1).
Figure 2. Masson’s trichrome staining and In situ hybridization. Masson’s trichrome stain was performed to localize collagen fibers (blue
stain, indicated by arrow) within myocardial sections of both control animals and animals that received CART. Significant fibrosis was not apparent in
any animals from either group (200X). Small numbers of infected cells (blue chromogen) were localized by in situ hybridization for SIV RNA in
myocardial sections from untreated, SIV-infected control macaques (C) and monkeys that received CART (D). NBT/BCIP chromogen (blue) with nuclear
fast red counterstain (100X).
doi:10.1371/journal.pone.0014429.g002
Figure 3. Activated macrophages are localized within inflammatory foci. Multiparameter immunohistochemistry and multispectral imaging
to localize the macrophage marker Iba-1 (green) and the activated macrophage marker CD68 (red). Double immunolabeling and spectral imaging
with pseudofluorescence coloring identifies Iba-1 expressing macrophages (green) within inflammatory foci (A). Expression of CD68 (red) identifies
activated macrophages within inflammatory foci (B). Nuclei are stained with Mayer’s hematoxylin counterstain (blue) (C). Note co-localization of all
CD68 expression within Iba-1 expressing cells (D) (arrows) (400X).
doi:10.1371/journal.pone.0014429.g003
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TNF-a in the myocardium of animals that received CART
We quantified mRNA transcripts for the proinflammatory
cytokine TNF-a in myocardial tissue from all animals in the
control, untreated and CART groups. Significantly greater levels
of TNF-a mRNA expression were measured in the myocardium of
animals that received CART than in myocardial tissue from the
untreated or control macaques (4.0560.19 vs. 3.4560.10 vs.
3.2560.20 log10 TNF-a copies/mg, respectively; p,0.05)
(Figure 6B). There was no difference in the quantity of TNF-a
mRNA transcripts measured in myocardial tissue from untreated
versus control groups.
Higher levels of CXCL9 (monokine induced by gamma
interferon) expression in the myocardium of animals that
received CART
Since macrophages were the principal cellular component of the
inflammatory and degenerative myocardial lesions observed in
Figure 4. CD8
+ T- and CD20
+ B-lymphocytes are not localized within inflammatory foci. Immunohistochemistry using anti-CD20 identified
a few B-lymphocytes in the inflammatory foci (arrows) (A). In contrast, no CD8
+ T-lymphocytes are localized using anti-CD8 antibody (B) (400X).
Immunohistrochemistry using anti-pro-IL-18 (C) or anti-CXCL9 (D) reveals the expression of these molecules on mononuclear cells within
inflammatory foci (200X).
doi:10.1371/journal.pone.0014429.g004
Figure 5. Lesions are composed of lymphocytes and macrophages. Double immunolabeling and spectral imaging with pseudofluorescence
coloring identifies CD4
+ T-lymphocytes and macrophages (red) within inflammatory foci (B). Expression of CD3 (green) identifies lymphocytes within
inflammatory foci (A). Nuclei are stained with Mayer’s hematoxylin (blue) (C). CD4
+ lymphocytes express both CD4 and CD3 molecules (arrows) (D).
Note CD3 expression on cells that do not express CD4 (arrowheads).
doi:10.1371/journal.pone.0014429.g005
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TNF-a mRNA expression had been measured in myocardial
specimens from the CART group, we sought to measure the levels
of mRNA expression for other key proinflammatory cytokines and
chemokines that have been implicated in the pathogenesis and
regulation of cytotoxic injury. To that end, we used SYBR Green
real time RT-PCR and gene specific primers to measure the
quantity of several mRNA transcripts, including IL-1b, IL-6, IL-
10, IL-18, INF-c, MCP-1, CXCL9 and CXCL11 in frozen
specimens of myocardial tissue from all three groups of animals.
Myocardial tissue from control animals expressed very low levels
of IL-1b, Il-6, IL-10, IL-18, CCR5 and INF-c mRNA, with cycle
threshold (Ct) values ranging from 33-37 (data not shown). In
contrast, appreciable levels of MCP-1, CXCL9, CXCL11 and
ICAM-1 mRNA were detected in controls, with Ct values ranging
from 27-31, indicating an abundance of expression of these genes
in the myocardium. Table 4 shows the expression patterns of
cytokines in the myocardium from untreated and CART groups of
SIV-positive monkeys as compared to the SIV-negative CD8-
depleted control group. Higher levels of CCR5, CXCL11, INF-c,
and IL-1b mRNA were expressed in the myocardium of SIV-
positive animals, regardless of whether they received antiretroviral
therapy, although the quantity of CXCL11 mRNA expressed in
SIV-infected, untreated macaques was more than two-fold greater
than in SIV-positive animals that received CART. The level of IL-
18 mRNA expression was lower in both treated and untreated
SIV-positive macaques, while IL-6 mRNA levels were similar to
SIV-negative controls. Interestingly, while the quantities of IL-10,
ICAM-1 and MCP-1 mRNA were similar in myocardial
specimens from SIV-positive macaques that received CART and
SIV-negative controls, greater quantities of all three transcripts
were measured in myocardial specimens from SIV-infected,
untreated animals than in the other two groups. In contrast,
while myocardial CXCL9 mRNA levels were similar between
SIV-negative animals and SIV-positive monkeys that received
CART, the quantity of myocardial CXCL9 transcripts was 7-fold
lower in untreated SIV-infected animals.
With regard to the relative magnitude of CXCL9 and ICAM-1
mRNA expression, differences between treated and untreated
SIV-positive macaques correlated precisely with the pattern of
protein expression in tissue sections by immunohistochemistry.
Strong expression of CXCL9 (which is induced by IFN-c) was
observed by the macrophages present in the inflammatory foci
(Figures 4B, 4C and 4D) in the myocardium of animals that
received CART, while CXCL9 expression was not detected in
sections of myocardium from untreated monkeys. Surprisingly, the
expression of ICAM-1, which is induced by TNF-a, was
significantly weaker in myocardial sections from animals that
received CART as opposed to SIV-infected, untreated monkeys
(Figure 7).
Discussion
The independent and combined contributions of HIV infection
and antiretroviral therapy on myocardial disease remain unclear;
thus, a reliable animal model would benefit efforts to distinguish
the impact of viral pathogenesis from antiretroviral toxicity. In this
retrospective study, we investigated the pathogenesis of myocar-
ditis in four of four CD8
+ cell-depleted, SIV-infected rhesus
macaques that had been treated for 28 days with PMPA and
RCV. Several potential etiologies could account for myocarditis in
these animals, including SIV infection, infection with opportunistic
agents, immune reconstitution inflammatory syndrome (IRIS),
autoimmunity, and antiretroviral toxicity. As described elsewhere,
CD3
+/CD8
+ T lymphocytes were persistently depleted from the
peripheral circulation in all SIV-positive animals for a minimum of
28 days post treatment with the CD8-depleting antibody, cM-
T807; however, peripheral CD8
+ T cells were partially restored in
all depleted animals prior to necropsy [35].
Figure 6. Quantification of virus burden and expression of TNF-a in myocardial tissue by real time RT-PCR. Tissue virus burdens were
significantly lower in the left ventricles of animals that received CART as compared to untreated controls (A). Horizontal bars represent median values
for each data set. Real-time RT-PCR with TNF-a specific TaqMan probe revealed significantly greater levels of TNF-a expression in the myocardium of
animals that received CART as compared to control animals (B). Note that TNF-a expression in the untreated group is similar to SIV-negative controls.
Horizontal bars represent median values for each data set.
doi:10.1371/journal.pone.0014429.g006
Table 4. Cytokine expression analysis.
Gene Untreated CART
IL-1b q 4.9502 q 4.6028
IL-6 1.7261 1.2946
IL-10 q 3.2378 1.4871
IL-18 Q 23.4702 Q 23.2378
INF-c q 5.1248 q 5.8361
CXCL9 Q 27.1354 1.3637
CXCL11 q 6.0945 q 2.7132
ICAM-1 q 4.0208 1.8693
MCP-1 q 2.2423 1.5263
CCR5 q 3.7451 q 3.1383
doi:10.1371/journal.pone.0014429.t004
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development of simian AIDS and had AIDS defining lesions at
necropsy; however, there were no significant inflammatory or
degenerative changes present in the myocardium of these animals.
The animals that received CART were electively sacrificed at 57
dpi, and were not clinically ill when euthanized, nor did they have
lesions indicative of simian AIDS at necropsy. Sections of
myocardium from animals that received CART contained
infiltrates of mononuclear inflammatory cells with cardiomyocy-
tolysis and cardiomyocyte atrophy. SIV has been associated with
myocarditis, and in severe cases, dilated cardiomyopathy in
chronically infected rhesus macaques [16,17]. The inflammatory
infiltrates that have been described previously for SIV-associated
myocarditis are similar to those of HIV myocarditis, and are
composed predominantly of CD8
+ T lymphocytes with variable
numbers of productively infected, SIV-positive macrophages and
multinucleated giant cells [16,17]. In our study, inflammatory foci
within the myocardium were dominated by macrophages, and
contained smaller numbers of CD3
+/CD4
+ T lymphocytes, but no
multinucleated giant cells, CD8
+ lymphocytes, or CD20
+ B
lymphocytes. The heart was not a primary target organ for SIV
in these CD8
+ cell-depleted animals, as very few SIV
+ cells were
localized in the myocardium of CART or untreated monkeys by
ISH, and significantly fewer copies of SIV RNA were measured by
real time RT-PCR in the myocardium of animals that received
CART as compared to untreated animals. Taken together, these
data provide strong evidence that the myocarditis present in the
CART group of animals is not due to SIV infection or an effect of
CD8
+ T lymphocyte depletion. The presence of ongoing
cardiomyocyte necrosis and the absence of myocardial fibrosis in
the CART group suggests that the myocardial lesions are active
but not chronic; however, we were unable to localize the temporal
onset of myocarditis in these animals, as neither functional
cardiovascular tests nor serum biochemical analyses specific to the
cardiovascular system were carried out during the course of the
study.
Both HIV-associated cardiomyopathy and chronic heart failure
have been associated with activation of the immune system leading
to the pathogenic overproduction of several proinflammatory
cytokines, including TNF-a, IL-1b, IL-6 and IL-18 [38,39].
Elevated local cardiac production and increased circulating levels
of TNF-a [40,41,42] have been implicated in cardiomyopathies of
various etiologies [43,44]. Yearley and colleagues recently
reported a direct relationship between dilated cardiomyopathy
and TNF-a expression in SIV-infected rhesus macaques [45]. In
this study, significantly greater levels of TNFa mRNA were
expressed in the myocardial tissue from the CART group
compared to the uninfected controls and SIV-infected untreated
animals, whereas there was no difference in the quantity of TNF-a
mRNA transcripts measured in spleen specimens from both
untreated macaques and those that received CART (data not
shown), suggesting similar systemic levels of TNF-a expression
among SIV infected animals. The effects of TNF-a expression in
the heart may have been augmented by increased myocardial IL-
1b production in SIV infected macaques, as the quantity of IL-1b
mRNA transcripts was elevated several fold in both the untreated
and CART groups of animals. We also found three-fold higher
expression of IL-10 mRNA in the untreated animals, which may
have diminished the synergistic effects of TNF-a and IL-1b in the
untreated group through its anti-inflammatory effects [46,47].
Taken together, these data strongly suggest that locally produced
myocardial TNF-a played a significant role in the pathogenesis of
the myocarditis that was observed selectively in monkeys that
received CART.
Interferon-gamma (IFN-c) is a pleiotropic cytokine that plays
important roles in both innate and adaptive, cell-mediated
immunity. The role for IFN-c is not as well established in the
pathogenesis of myocardial disease; however, transgenic mice that
Figure 7. ICAM-1 expression in myocardial sections. IHC for ICAM-1, localizing increased ICAM-1 expression to endothelial cells in non-
inflamed myocardium of SIV positive, untreated rhesus macaques (A) as opposed to SIV infected monkeys that received CART (B). Increased ICAM-1
expression was also localized to mononuclear inflammatory cell infiltrates in animals that received antiretroviral therapy (C). Higher magnification of
inflammatory foci (1,000X) (D). Immunoperoxidase immunohistochemistry, with DAB chromogen (brown) and hematoxylin counterstain.
doi:10.1371/journal.pone.0014429.g007
Myocarditis and CART
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14429constitutively express IFN-c in liver tissue driven by the liver
specific promoter of human serum amyloid P component (SAP)
gene were recently shown to develop chronic active myocarditis
and cardiomyopathy [48]. We measured mRNA transcripts for
IFN-c and the IFN-c-inducible T cell-chemoattractant genes
CXCL11 (I-TAC) and CXCL9 (MIG) in the myocardium from all
three groups of monkeys. Compared to control macaques, six- and
three-fold higher quantities of CXCL11 mRNA were expressed in
the myocardial tissue of the SIV-infected untreated and CART
groups, respectively. In contrast, seven-fold lower levels of CXCL9
mRNA were measured in the myocardium of untreated macaques
compared to the control and CART groups. These results
correlated favorably with the levels of CXCL9 protein expression
observed by IHC, as higher levels of CXCL9 were localized in
myocardial endothelial cells and intralesional macrophages in the
myocardium of animals that received CART than in untreated
macaques. Since TNF-a and IFN-c can increase endothelial
CXCL9 expression [49], increased TNF-a and IFN-c mRNA
expression may have induced CXCL9 expression and facilitated
myocarditis in the macaques that received CART.
Despite the presence of myocarditis, macaques in the CART
group expressed lower quantities of MCP-1 and ICAM-1 mRNA
in myocardial tissue compared to untreated animals. It is unclear
why the MCP-1 mRNA levels were lower in animals with
lymphohistiocytic inflammation. However, in the case of ICAM-1,
this unexpected result was explained by IHC, which revealed
significant diffuse ICAM-1 expression in SIV-infected untreated
animals, which was localized to endothelial cells in the non-
inflamed myocardium. In contrast, in infected animals that
received CART, ICAM-1 expression was confined to inflamma-
tory foci. Since HIV gp120 has been shown to increase endothelial
expression of ICAM-1 in vitro [50], we hypothesize that SIV-
infection resulted in diffuse upregulation of ICAM-1 expression by
myocardial endothelial cells.
Elevated levels of IL-18 mRNA have been measured in the
myocardium of mice after the induction of myocardial infarction
[51], while both increased [52] and decreased [53] IL-18 mRNA
expression have been reported in myocardial tissue from human
patients with ischemic and dilated cardiomyopathy. Surprisingly,
despite increased expression of TNF-a and IL-1b mRNA, we
observed a three-fold decrease in IL-18 mRNA expression in
myocardial tissue from monkeys in the CART group as compared
to controls. However, since IL-18 is regulated post-transcription-
ally by caspase-1 and IL-18 binding protein, mRNA levels are not
necessarily predictive of IL-18 activity [54,55]. In the present
study, IHC using an anti-pro-IL-18 antibody resulted in faint
intracytoplasmic reactivity of macrophages within inflammatory
foci; however, the expression of mature IL-18 protein could not be
evaluated due to the lack of antibodies suitable for the detection of
mature, cleaved IL-18 in macaque tissues.
We have considered several etiologic scenarios as possible
explanations for lymphohistiocytic myocarditis in SIV-positive,
CD8-depleted rhesus macaques after short-term treatment with
RCV and PMPA, including: SIV infection, infection with
opportunistic agents, IRIS and antiretroviral toxicity. We did
not measure anti-desmin antibodies or pursue other methods to
explore potential autoimmune mechanisms as a cause for these
lesions. Since the SIV burdens in heart tissue were lower in the
CART group macaques than the untreated animals, the animals
were not clinically ill, and no opportunistic agents were identified,
we believe that the myocarditis is due to the treatment with two
NRTIs, resulting in cardiomyocyte injury and necrosis, subsequent
mononuclear cell recruitment, lymphohistiocytic infiltration, and
increased cardiac expression of TNF-a and CXCL9 in the affected
animals. PMPA (Tenofovir or Viread) manufactured by Gilead
has been a part of many of the HAART regimens used to treat
HIV-infected humans [56,57], however, RCV has not been used
for therapeutic purposes. Several studies have shown the
association between treatment with NRTIs and cardiotoxicity
and cardiovascular problems in humans. However, the toxico-
pathological impact of treatment with antiretroviral regimens
containing multiple NRTIs has not been addressed in detail [30].
Prospective studies with the CD8-depleted, SIV/macaque model
that include functional examination of the cardiovascular system
will facilitate elucidation of the mechanism of myocardial toxicities
that result from combined NRTI therapy.
Author Contributions
Conceived and designed the experiments: LA. Performed the experiments:
LA HD DW. Analyzed the data: LA SW SPO. Contributed reagents/
materials/analysis tools: GG SPO. Wrote the paper: LA SW GG SPO.
References
1. Reilly JM, Cunnion RE, Anderson DW, O’Leary TJ, Simmons JT, et al. (1988)
Frequency of myocarditis, left ventricular dysfunction and ventricular tachycar-
dia in the acquired immune deficiency syndrome. Am J Cardiol 62: 789–
793.
2. Anderson DW, Virmani R, Reilly JM, O’Leary T, Cunnion RE, et al. (1988)
Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome.
J Am Coll Cardiol 11: 792–799.
3. Baroldi G, Corallo S, Moroni M, Repossini A, Mutinelli MR, et al. (1988) Focal
lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): a
correlative morphologic and clinical study in 26 consecutive fatal cases. J Am
Coll Cardiol 12: 463–469.
4. Zareba KM, Lipshultz SE (2003) Cardiovascular Complications in Patients with
HIV Infection. Curr Infect Dis Rep 5: 513–520.
5. Starc TJ, Lipshultz SE, Easley KA, Kaplan S, Bricker JT, et al. (2002) Incidence
of cardiac abnormalities in children with human immunodeficiency virus
infection: The prospective P2C2 HIV study. J Pediatr 141: 327–334.
6. Klatt EC (2003) Cardiovascular pathology in AIDS. Adv Cardiol 40: 23–
48.
7. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, et al. (2003) Coronary
heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33:
506–512.
8. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S (2002) Do protease
inhibitors increase the risk for coronary heart disease in patients with HIV-1
infection? J Acquir Immune Defic Syndr 30: 471–477.
9. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, et al. (2002)
Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet
360: 1747–1748.
10. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular
and cerebrovascular events in patients treated for human immunodeficiency
virus infection. N Engl J Med 348: 702–710.
11. Triant VA, Lee H, Hadigan C, Grinspoon SK (2007) Increased acute
myocardial infarction rates and cardiovascular risk factors among patients with
human immunodeficiency virus disease. J Clin Endocrinol Metab 92:
2506–2512.
12. Sani MU (2008) Myocardial disease in human immunodeficiency virus (HIV)
infection: a review. Wien Klin Wochenschr 120: 77–87.
13. Herskowitz A, Wu TC, Willoughby SB, Vlahov D, Ansari AA, et al. (1994)
Myocarditis and cardiotropic viral infection associated with severe left
ventricular dysfunction in late-stage infection with human immunodeficiency
virus. J Am Coll Cardiol 24: 1025–1032.
14. Grody WW, Cheng L, Lewis W (1990) Infection of the heart by the human
immunodeficiency virus. Am J Cardiol 66: 203–206.
15. Fiala M, Popik W, Qiao JH, Lossinsky AS, Alce T, et al. (2004) HIV-1 induces
cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine
apoptotic signaling. Cardiovasc Toxicol 4: 97–107.
16. Shannon RP, Simon MA, Mathier MA, Geng YJ, Mankad S, et al. (2000)
Dilated cardiomyopathy associated with simian AIDS in nonhuman primates.
Circulation 101: 185–193.
17. Yearley JH, Pearson C, Carville A, Shannon RP, Mansfield KG (2006) SIV-
associated myocarditis: viral and cellular correlates of inflammation severity.
AIDS Res Hum Retroviruses 22: 529–540.
18. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, et al. (2000) Impact of
highly active antiretroviral therapy in HIV-positive patients with cardiac
involvement. J Infect 40: 282–284.
Myocarditis and CART
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e1442919. Clumeck N, De Wit S (2000) Update on highly active antiretroviral therapy:
progress and strategies. Biomed Pharmacother 54: 7–12.
20. Richman DD (2001) HIV chemotherapy. Nature 410: 995–1001.
21. Vittecoq D, Escaut L, Merad M, Teicher E, Monsuez JJ, et al. (2003) Coronary
heart disease in HIV-infected individuals. Adv Cardiol 40: 151–162.
22. Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, et al. (2002) Use of HIV
protease inhibitors is associated with left ventricular morphologic changes and
diastolic dysfunction. J Acquir Immune Defic Syndr 30: 306–310.
23. Mu H, Chai H, Lin PH, Yao Q, Chen C (2007) Current update on HIV-
associated vascular disease and endothelial dysfunction. World J Surg 31:
632–643.
24. Rogers JS, Zakaria S, Thom KA, Flammer KM, Kanno M, et al. (2008)
Immune reconstitution inflammatory syndrome and human immunodeficiency
virus-associated myocarditis. Mayo Clin Proc 83: 1275–1279.
25. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, et al.
(2003) Combination antiretroviral therapy and the risk of myocardial infarction.
N Engl J Med 349: 1993–2003.
26. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. (2003)
Cardiovascular disease risk factors in HIV patients–association with antiretro-
viral therapy. Results from the DAD study. Aids 17: 1179–1193.
27. Sklar P, Masur H (2003) HIV infection and cardiovascular disease-is there really
a link? N Engl J Med 349: 2065–2067.
28. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD (1992)
Cardiomyopathy associated with antiretroviral therapy in patients with HIV
infection: a report of six cases. Ann Intern Med 116: 311–313.
2 9 .L e w i sW ,P a p o i a nT ,G o n z a l e zB ,L o u i eH ,K e l l yD P ,e ta l .( 1 9 9 1 )
Mitochondrial ultrastructural and molecular changes induced by zidovudine
in rat hearts. Lab Invest 65: 228–236.
30. Fantoni M, Autore C, Del Borgo C (2001) Drugs and cardiotoxicity in HIV and
AIDS. Ann N Y Acad Sci 946: 179–199.
31. Lewis W, Simpson JF, Meyer RR (1994) Cardiac mitochondrial DNA
polymerase-gamma is inhibited competitively and noncompetitively by phos-
phorylated zidovudine. Circ Res 74: 344–348.
32. Barile M, Valenti D, Quagliariello E, Passarella S (1998) Mitochondria as cell
targets of AZT (zidovudine). Gen Pharmacol 31: 531–538.
33. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP (1998)
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as
common pathway. Aids 12: 1735–1744.
34. Mondal D, Pradhan L, Ali M, Agrawal KC (2004) HAART drugs induce
oxidative stress in human endothelial cells and increase endothelial recruitment
of mononuclear cells: exacerbation by inflammatory cytokines and amelioration
by antioxidants. Cardiovasc Toxicol 4: 287–302.
35. Williams K, Westmoreland S, Greco J, Ratai E, Lentz M, et al. (2005) Magnetic
resonance spectroscopy reveals that activated monocytes contribute to neuronal
injury in SIV neuroAIDS. J Clin Invest 115: 2534–2545.
36. O’Neil SP, Suwyn C, Anderson DC, Niedziela G, Bradley J, et al. (2004)
Correlation of acute humoral response with brain virus burden and survival time
in pig-tailed macaques infected with the neurovirulent simian immunodeficiency
virus SIVsmmFGb. Am J Pathol 164: 1157–1172.
37. Yearley JH, Xia D, Pearson CB, Carville A, Shannon RP, et al. (2009)
Interleukin-18 predicts atherosclerosis progression in SIV-infected and unin-
fected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet. Lab
Invest 89: 657–667.
38. Mari D, Di Berardino F, Cugno M (2002) Chronic heart failure and the immune
system. Clin Rev Allergy Immunol 23: 325–340.
39. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D (2007) Cytokines in
HIV-associated cardiomyopathy. Int J Cardiol 120: 150–157.
40. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S (1994) Vesnarinone, a
new inotropic agent, inhibits cytokine production by stimulated human blood
from patients with heart failure. Circulation 89: 955–958.
41. Calabrese F, Carturan E, Chimenti C, Pieroni M, Agostini C, et al. (2004)
Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I
in human viral myocarditis: clinicopathologic correlations. Mod Pathol 17:
1108–1118.
42. Bilate AM, Salemi VM, Ramires FJ, de Brito T, Russo M, et al. (2007) TNF
blockade aggravates experimental chronic Chagas disease cardiomyopathy.
Microbes Infect 9: 1104–1113.
43. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, et al. (1996)
Tumour necrosis factor and inducible nitric oxide synthase in dilated
cardiomyopathy. Lancet 347: 1151–1155.
44. Wang M, Tsai BM, Crisostomo PR, Meldrum DR (2006) Tumor necrosis factor
receptor 1 signaling resistance in the female myocardium during ischemia.
Circulation 114: I282–289.
45. Yearley JH, Mansfield KG, Carville AA, Sokos GG, Xia D, et al. (2008)
Antigenic stimulation in the simian model of HIV infection yields dilated
cardiomyopathy through effects of TNFalpha. Aids 22: 585–594.
46. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991) IL-10
inhibits cytokine production by activated macrophages. J Immunol 147:
3815–3822.
47. Bolger AP, Sharma R, von Haehling S, Doehner W, Oliver B, et al. (2002) Effect
of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral
blood mononuclear cells from patients with chronic heart failure. Am J Cardiol
90: 384–389.
48. Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, et al. (2007)
Interferon-gamma induces chronic active myocarditis and cardiomyopathy in
transgenic mice. Am J Pathol 171: 463–472.
49. Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, et al. (2006) TLR ligands
and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in
autoimmune arthritis. Lab Invest 86: 902–916.
50. Ren Z, Yao Q, Chen C (2002) HIV-1 envelope glycoprotein 120 increases
intercellular adhesion molecule-1 expression by human endothelial cells. Lab
Invest 82: 245–255.
51. Woldbaek PR, Tonnessen T, Henriksen UL, Florholmen G, Lunde PK, et al.
(2003) Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after
myocardial infarction in the mouse; a potential role in cardiac dysfunction.
Cardiovasc Res 59: 122–131.
52. Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, et al. (2004) Evidence for
altered interleukin 18 (IL)-18 pathway in human heart failure. Faseb J 18:
1752–1754.
53. Westphal E, Rohrbach S, Buerke M, Behr H, Darmer D, et al. (2008) Altered
interleukin-1 receptor antagonist and interleukin-18 mRNA expression in
myocardial tissues of patients with dilatated cardiomyopathy. Mol Med 14:
55–63.
54. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, et al. (1997) Caspase-1
processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma
production. Nature 386: 619–623.
55. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, et al. (1999)
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response.
Immunity 10: 127–136.
56. Srinivas RV, Fridland A (1998) Antiviral activities of 9-R-2-phosphonomethox-
ypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against
various drug-resistant human immunodeficiency virus strains. Antimicrob
Agents Chemother 42: 1484–1487.
57. Miller MD, Margot NA, Hertogs K, Larder B, Miller V (2001) Antiviral activity
of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
Nucleosides Nucleotides Nucleic Acids 20: 1025–1028.
Myocarditis and CART
PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e14429